| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shepard Jay |
President and CEO |
• • – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
189,000 |
393,744 |
|
- |
|
| Brumm Joshua T |
COO and CFO |
• – – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
97,000 |
202,595 |
|
- |
|
| Ward Shane |
SVP and General Counsel |
• – – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
57,000 |
93,350 |
|
- |
|
| Stout Jay S |
SVP, Technical Operations |
• – – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
116,000 |
|
- |
|
| Gut Robert |
Chief Medical Officer |
• – – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
88,000 |
136,000 |
|
- |
|
| Westberg Paul |
SVP and Chief Business Officer |
• – – |
2017-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
59,000 |
126,517 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2017-09-22 |
4 |
S |
$3.03 |
$5,281,750 |
I/I |
(1,650,000) |
2,099,563 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2017-09-21 |
4 |
S |
$3.56 |
$1,731,802 |
I/I |
(480,000) |
3,749,563 |
|
- |
|
| Gut Robert |
Chief Medical Officer |
• – – |
2017-09-05 |
4 |
A |
$0.00 |
$0 |
D/D |
48,000 |
48,000 |
|
- |
|
| Westberg Paul |
SVP and Chief Business Officer |
• – – |
2017-06-13 |
4 |
S |
$16.05 |
$11,412 |
D/D |
(711) |
67,517 |
|
- |
|
| Brumm Joshua T |
COO and CFO |
• – – |
2017-06-13 |
4 |
S |
$16.05 |
$22,807 |
D/D |
(1,421) |
105,595 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
14,955 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
33,180 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
12,680 |
|
- |
|
| Jennings Edmon R |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
11,180 |
|
- |
|
| Varian John |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
11,080 |
|
- |
|
| Dobmeier Eric |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,960 |
6,960 |
|
- |
|
| Sun Anthony Y |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
12,680 |
|
- |
|
| Brumm Joshua T |
COO and CFO |
• – – |
2017-05-16 |
4 |
S |
$17.40 |
$21,976 |
D/D |
(1,263) |
107,016 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2017-05-11 |
4 |
S |
$17.50 |
$159,495 |
D/D |
(9,114) |
204,744 |
|
- |
|
| Westberg Paul |
SVP and Chief Business Officer |
• – – |
2017-04-19 |
4 |
S |
$19.85 |
$26,123 |
D/D |
(1,316) |
68,228 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2017-04-04 |
4 |
AS |
$21.20 |
$742,000 |
D/D |
(35,000) |
24,500 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2017-04-04 |
4 |
OE |
$8.17 |
$285,950 |
D/D |
35,000 |
59,500 |
|
- |
|
| Stout Jay S |
SVP, Technical OperationsOffic |
• – – |
2017-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
| Stout Jay S |
SVP, Technical Operations |
• – – |
2017-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
46,000 |
|
- |
|
258 Records found
|
|
Page 4 of 11 |
|
|
